-
Innovation Ranking
NewInnovation Ranking – Kyowa Kirin Co Ltd
Kyowa Kirin Co Ltd (Kyowa Kirin), a subsidiary of Kirin Holdings Co Ltd, is a biotechnology company focused on research and development. It is involved in the discovery, development, production and commercialization of pharmaceuticals and biotechnology products. The company offers drugs in the areas of nephrology, oncology, immunology and allergy, central nervous system among others. Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, angina pectoris, hypertension,...
-
Innovation Ranking
NewInnovation Ranking – Kirin Holdings Co Ltd
Kirin Holdings Co Ltd (Kirin) manufactures and markets alcoholic and non-alcoholic beverages and pharmaceuticals products. Its major products include beer, wine, hopposhu, new genre, sprits, chu-hi, whiskey, seltzer, kombucha, black tea, coffee, tea, fruit juice, dairy products, carbonated beverages, health/sports beverages, ionized natural water, and pharmaceutical drugs. The company markets its products under Kirin Hyoketsu, Honkirin, James Squire, iMUSE, Cognizin, Kirin Gogo-no-Kocha, Kirin Nama-cha, XXXX, Kirin Ichiban, Berri, Baden, San Miguel Pale Pilsen, Spring Valley, Kirin Nodogoshi Nama, Kirin FREE,...
-
Sector Analysis
NewCell and Gene Therapies in CNS Disorders – Disease Overview, Treatment Options and Future Market Assessment
Cell and Gene Therapies in CNS Disorders Market Report Overview The cell and gene therapies (CGT) sales in central nervous system (CNS) disorders was $1.5 billion in 2023. It will experience significant growth, achieving a CAGR of more than 42% during the forecast period. Gene therapies will dominate the CGT market in CNS disorders because of strong players such as Sarepta Therapeutics and Novartis with marketed products Elevidys and Zolgensma, respectively. Cell and Gene Therapies in CNS Disorders Market Outlook...
-
Product Insights
NewNet Present Value Model: Ionis Pharmaceuticals Inc’s Evazarsen Sodium
Empower your strategies with our Net Present Value Model: Ionis Pharmaceuticals Inc's Evazarsen Sodium report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Kyowa Kirin Co Ltd’s Rocatinlimab
Empower your strategies with our Net Present Value Model: Kyowa Kirin Co Ltd's Rocatinlimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mogamulizumab in Peripheral T-Cell Lymphomas (PTCL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mogamulizumab in Peripheral T-Cell Lymphomas (PTCL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mogamulizumab in Peripheral T-Cell Lymphomas (PTCL) Drug Details: Mogamulizumab...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Oncolytic Virus To Target CD46 And SLC5A5 For Oncology in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Oncolytic Virus To Target CD46 And SLC5A5 For Oncology in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Oncolytic Virus To...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cedazuridine + Decitabine) in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cedazuridine + Decitabine) in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cedazuridine + Decitabine) in Solid Tumor Drug Details: Cedazuridine...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rocatinlimab in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rocatinlimab in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rocatinlimab in Atopic Dermatitis (Atopic Eczema) Drug Details: Rocatinlimab is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mogamulizumab in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mogamulizumab in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mogamulizumab in Adenocarcinoma Of The Gastroesophageal Junction Drug...